Menstrual Disorders Practice Questions

Q: Withdrawal bleeding with progesterone is seen in an otherwise amenorrheic woman due to which of the following?

Anovulation. **Explanation:** The **Progesterone Challenge Test (PCT)** is a fundamental diagnostic tool in amenorrhea. For withdrawal bleeding to occur after progesterone administration, two physiological prerequisites must be met: 1. **Endometrial Priming:** The endometrium must have been previously exposed to endogenous **estrogen**, causing it to proliferate. 2. **Patent Outflow Tract:** There must be a functional uterus, cervix, and vagina. In **Anovulation (Option B)**, the ovaries produce estrogen (leading to endometrial proliferation), but because ovulation does not occur, no corpus luteum is formed and no progesterone is produced. This results in a state of "unopposed estrogen." Administering exogenous progesterone and then stopping it mimics the natural decline of the corpus luteum, causing the primed endometrium to shed (withdrawal bleed). **Why other options are incorrect:** * **Hypogonadotropic Hypogonadism (Option A):** Low FSH/LH levels lead to minimal estrogen production. Without estrogen to prime the endometrium, progesterone cannot cause a withdrawal bleed. * **Ovarian Failure (Option C):** In Premature Ovarian Failure, the follicles are depleted. Estrogen levels are critically low, resulting in a negative PCT. * **Tuberculous Endometritis (Option D):** This causes destruction of the endometrial lining or synechiae (Asherman-like syndrome). Even with adequate hormones, there is no functional tissue to shed. **NEET-PG High-Yield Pearls:** * **Positive PCT:** Confirms anovulation (e.g., PCOS) and implies adequate endogenous estrogen. * **Negative PCT:** Indicates either **low estrogen** (Hypothalamic/Ovarian failure) or an **outflow tract obstruction** (Asherman’s/Mulleris agenesis). * The next step after a negative PCT is the **Estrogen-Progesterone Challenge Test** to differentiate between low estrogen and anatomical defects.

Q: A 48-year-old woman, P2L2, with menorrhagia, diagnosed with adenomyosis, is not responding to medical management with NSAIDs and hormonal therapy. What is the next step in management?

Hysteroscopy biopsy. **Explanation:** The correct answer is **D. Hysteroscopy biopsy**. **1. Why Hysteroscopy Biopsy is the Correct Next Step:** In a 48-year-old woman presenting with Abnormal Uterine Bleeding (AUB) that is refractory to medical management, the primary clinical priority is to **exclude endometrial hyperplasia or malignancy**. According to FIGO and ACOG guidelines, any woman over the age of 45 with AUB (or younger with risk factors) must undergo endometrial sampling. Even if a diagnosis of adenomyosis has been made clinically or via ultrasound, the failure of medical therapy necessitates a pathological evaluation of the endometrium before proceeding to definitive surgical interventions. **2. Why Other Options are Incorrect:** * **A. Mirena (LNG-IUD):** While Mirena is an excellent second-line medical treatment for adenomyosis, it should not be initiated in a perimenopausal woman with persistent bleeding until the endometrium has been sampled to rule out malignancy. * **B. GnRH Analogues:** These are generally used as a short-term "bridge" to surgery or to shrink the uterus; they do not provide a definitive diagnosis and are not the immediate next step when malignancy needs to be excluded. * **C. Hysterectomy:** This is the definitive treatment for adenomyosis. However, performing a major surgery without first ruling out endometrial cancer via biopsy is considered poor clinical practice, as the presence of malignancy would alter the surgical approach (e.g., staging, lymphadenectomy). **Clinical Pearls for NEET-PG:** * **Gold Standard Diagnosis for Adenomyosis:** Histopathology (post-hysterectomy). * **Investigation of Choice (Imaging):** MRI (shows thickening of the Junctional Zone >12mm). * **Rule of Thumb:** In any perimenopausal/postmenopausal bleeding, **"Rule out Cancer first"** via Endometrial Biopsy or D&C. * **Definitive Treatment:** Hysterectomy is the only cure for adenomyosis.

Q: Which of the following IUDs is used for patients with menorrhagia?

Progestase (Levonorgestrel). **Explanation:** The correct answer is **D. Progestase (Levonorgestrel)**. **Why it is correct:** The Levonorgestrel-releasing Intrauterine System (LNG-IUS), commonly known by brand names like Mirena or Progestasert/Progestase, is the only IUD indicated for the treatment of **menorrhagia** (heavy menstrual bleeding). It works by releasing a low dose of progestogen directly into the uterine cavity, which causes profound **endometrial atrophy** and thinning. This leads to a significant reduction in menstrual blood loss (up to 90%) and often results in amenorrhea. It is considered a first-line medical management for Idiopathic Menorrhagia and is also used in cases of adenomyosis and endometriosis. **Why the other options are incorrect:** * **A, B, and C (CuT 250, Multiload, Nova T):** These are all **Copper-containing IUDs**. Copper IUDs are non-hormonal and work primarily by causing a sterile inflammatory response in the endometrium. A well-known side effect of copper IUDs is an **increase in menstrual blood loss** and dysmenorrhea. Therefore, they are contraindicated in patients already suffering from menorrhagia. **High-Yield Clinical Pearls for NEET-PG:** * **Mechanism of LNG-IUS:** Thickens cervical mucus (primary), causes endometrial atrophy, and inhibits sperm motility. * **Life Span:** LNG-IUS (Mirena) is typically effective for 5–8 years. * **Non-contraceptive benefits:** Reduces the risk of Pelvic Inflammatory Disease (PID) due to thickened cervical mucus and protects against endometrial hyperplasia/cancer. * **Ideal Candidate:** A woman with heavy periods who also requires long-term, reversible contraception.

Q: A 34-year-old woman presents with abnormal uterine bleeding. Which of the following is the LEAST likely cause of abnormal bleeding in this age group?

Endometrial atrophy. **Explanation:** The correct answer is **Endometrial atrophy**. Abnormal Uterine Bleeding (AUB) in reproductive-age women (typically 15–45 years) is classified by the **FIGO PALM-COEIN** criteria. In a 34-year-old woman, the uterus is under the constant influence of estrogen, which promotes endometrial proliferation. **Endometrial atrophy** occurs due to a state of estrogen deficiency, making it the hallmark cause of postmenopausal bleeding. It is highly unlikely in a woman of reproductive age unless there is severe premature ovarian insufficiency or prolonged use of certain hormonal contraceptives (e.g., DMPA). **Analysis of Incorrect Options:** * **Adenomyosis (A):** Common in women in their 30s and 40s, typically presenting with heavy menstrual bleeding (HMB) and dysmenorrhea. * **Fibroids (B):** Leiomyomas are the most common benign tumors in women of reproductive age and a leading cause of HMB and pelvic pressure. * **Polyps (C):** Endometrial polyps are frequent causes of intermenstrual bleeding and AUB in the premenopausal age group. **NEET-PG High-Yield Pearls:** * **Most common cause of AUB in postmenopausal women:** Endometrial atrophy (60-80%), though malignancy must always be ruled out. * **Most common cause of AUB in adolescents:** Anovulation due to an immature Hypothalamic-Pituitary-Ovarian (HPO) axis. * **Gold Standard Investigation for AUB:** Hysteroscopy (allows direct visualization and directed biopsy). * **First-line investigation:** Transvaginal Ultrasound (TVS).

Q: In a patient with secondary amenorrhea who does not experience withdrawal bleeding after estrogen and progesterone administration, the underlying issue is most likely at which level?

Endometrium. This question tests the understanding of the **stepwise evaluation of secondary amenorrhea**. ### **Explanation of the Correct Answer** The **Estrogen-Progesterone Challenge Test** is the final step in localizing the cause of amenorrhea. 1. **Estrogen** is given to prime the endometrium (proliferation). 2. **Progesterone** is then given to induce secretory changes. 3. Upon withdrawal, if the outflow tract is patent and the endometrium is functional, **withdrawal bleeding must occur.** If there is **no bleeding** after this combined therapy, it indicates that the target organ—the **endometrium**—is either absent, damaged, or the outflow tract is obstructed. This is characteristic of **Asherman’s Syndrome** (intrauterine synechiae) or **Müllerian agenesis** (though the latter usually presents as primary amenorrhea). ### **Why Other Options are Incorrect** * **A & B (Pituitary & Hypothalamus):** If the defect were at the level of the brain (low GnRH or FSH/LH), the endometrium would still be responsive. Providing exogenous estrogen and progesterone bypasses the brain, so these patients **would** experience withdrawal bleeding. * **C (Ovary):** In premature ovarian failure, the endogenous estrogen is low, but the endometrium remains responsive. These patients **would** bleed after receiving exogenous hormones. ### **High-Yield NEET-PG Clinical Pearls** * **Step 1:** Rule out pregnancy (most common cause of secondary amenorrhea). * **Step 2:** Progesterone Challenge Test (PCT). If bleeding occurs = **Anovulation** (e.g., PCOS). * **Step 3:** If PCT is negative, perform the Estrogen + Progesterone Challenge. * **Negative E+P Challenge:** Confirms **End-organ failure** (Asherman’s Syndrome). * **Gold Standard Investigation** for Asherman’s Syndrome: **Hysteroscopy.**

Q: What is the preferred method of contraception for managing menorrhagia?

Levonorgestrel-releasing IUD (LNG IUD). ### Explanation **Correct Answer: C. Levonorgestrel-releasing IUD (LNG IUD)** The **LNG IUD (Mirena)** is the preferred contraceptive method for managing menorrhagia (Heavy Menstrual Bleeding) because it acts directly on the endometrium. It releases a steady dose of levonorgestrel, which leads to **endometrial atrophy** and down-regulation of estrogen receptors. This results in a significant reduction in menstrual blood loss (up to 90% within 3–6 months) and often leads to amenorrhea. It is considered a first-line medical management for idiopathic menorrhagia, often preventing the need for surgical interventions like hysterectomy. **Analysis of Incorrect Options:** * **A. Modified IUD:** This is a vague term. While some modified frames exist, they do not possess the specific hormonal properties required to treat menorrhagia. * **B. Cu-T (Copper T):** This is **contraindicated** in patients with menorrhagia. A common side effect of copper-bearing IUDs is an *increase* in menstrual blood loss and dysmenorrhea due to a local inflammatory response. * **D. Condom:** While an effective barrier contraceptive, it has no hormonal influence on the menstrual cycle and provides no therapeutic benefit for heavy bleeding. **High-Yield Clinical Pearls for NEET-PG:** * **Gold Standard:** LNG IUD is the most effective non-surgical treatment for Heavy Menstrual Bleeding (HMB). * **Pearl:** It is also used in the management of endometriosis, adenomyosis, and endometrial hyperplasia without atypia. * **Failure Rate:** The Pearl Index of LNG IUD is approximately **0.2**, making it as effective as sterilization. * **Life Span:** The standard LNG IUD (52mg) is FDA-approved for **8 years** for contraception (though often cited as 5 years for menorrhagia).

Q: Massive painless vaginal bleeding after a 6-8 week period of amenorrhea, in a premenopausal woman, is suggestive of?

Metropathia haemorrhagica. **Explanation:** **Metropathia Haemorrhagica (Schroeder’s Disease)** is a specialized form of Dysfunctional Uterine Bleeding (DUB) typically seen in perimenopausal women. It occurs due to **persistent unovulation**. 1. **Why it is correct:** The pathophysiology involves a single follicle that matures but fails to rupture (no ovulation). This leads to a state of **unopposed estrogen** with an absolute absence of progesterone. The estrogen causes the endometrium to proliferate excessively (hyperplasia). Eventually, the estrogen levels fluctuate or the endometrium outgrows its blood supply, leading to **painless, massive, and prolonged bleeding** following a period of amenorrhea (usually 6-8 weeks). This classic clinical triad is often referred to as the "Metropathic pattern." 2. **Why other options are incorrect:** * **Irregular Ripening:** Caused by poor corpus luteum function (progesterone deficiency). It presents as premenstrual spotting, not massive bleeding after amenorrhea. * **Irregular Shedding (Halban Disease):** Caused by a persistent corpus luteum. It presents as prolonged, heavy bleeding, but the bleeding starts *on time* with the expected menses, not after a period of amenorrhea. * **Endometrial Carcinoma:** While it causes abnormal bleeding in older women, it typically presents as postmenopausal bleeding or intermenstrual bleeding, rather than the specific cyclic pattern of amenorrhea followed by flooding. **High-Yield Clinical Pearls for NEET-PG:** * **Characteristic Finding:** On D&C, the endometrium shows **Swiss-Cheese Hyperplasia** (cystic glandular hyperplasia). * **Ovarian Finding:** Presence of a follicular cyst (Amnestic follicle) on one ovary; the other ovary is usually small/atrophic. * **Uterine Finding:** The uterus is often symmetrically enlarged (myohyperplasia) due to prolonged estrogen stimulation.

Q: Which of the following is NOT a feature of Metropathia haemorrhagica?

Occurs in younger women. **Explanation:** **Metropathia Haemorrhagica** (also known as Schroeder’s Disease) is a specific form of Abnormal Uterine Bleeding (AUB) associated with anovulation. **1. Why Option A is the correct answer:** Metropathia haemorrhagica typically occurs in **perimenopausal women** (women in their 40s), not younger women. The underlying pathology is the persistence of an unruptured Graafian follicle, leading to a prolonged follicular phase without ovulation. This results in a period of amenorrhea (usually 6–8 weeks) followed by heavy, painless bleeding. **2. Analysis of incorrect options:** * **B. Uterus is bulky:** Due to the continuous, unopposed stimulation of estrogen without the counter-effect of progesterone (since no corpus luteum is formed), the myometrium undergoes hypertrophy, making the uterus feel symmetrically bulky (myometrial hyperplasia). * **C. Menorrhagia:** The hallmark clinical presentation is heavy, prolonged, and painless bleeding. Because the endometrium outgrows its blood supply in the absence of progesterone, it sheds irregularly and profusely. * **D. Endometrial hyperplasia:** Continuous estrogen causes the endometrium to become hyperplastic. Classically, this presents as **Swiss-cheese endometrium** (Cystoglandular hyperplasia), where glands of varying sizes are seen on histopathology. **NEET-PG High-Yield Pearls:** * **Classic Triad:** Amenorrhea (short period) → Followed by profuse, painless bleeding → In a perimenopausal woman. * **Ovarian finding:** Presence of a follicular cyst (unruptured follicle) and absence of corpus luteum. * **Histology:** "Swiss-cheese" appearance of the endometrium. * **Treatment of choice:** Dilatation and Curettage (D&C) serves both a diagnostic and therapeutic purpose (to stop the bleeding).

Q: Secondary amenorrhea after abortion due to intrauterine adhesions is seen in:

Asherman's syndrome. **Explanation:** **Asherman’s Syndrome** is the correct answer because it refers to the formation of intrauterine adhesions (synechiae) following trauma to the basal layer of the endometrium. This most commonly occurs after vigorous curettage (D&C) for an incomplete abortion or postpartum hemorrhage. The destruction of the endometrium leads to the fusion of the uterine walls, resulting in secondary amenorrhea or hypomenorrhea and infertility. **Analysis of Incorrect Options:** * **Uterine Inertia:** This refers to weak or absent uterine contractions during labor (primary or secondary). It is a functional complication of the first or second stage of labor and has no association with intrauterine adhesions or amenorrhea. * **Imperforate Hymen:** This is a congenital anatomical cause of **primary amenorrhea**. It leads to cryptomenorrhea (hidden menstruation) where blood collects in the vagina (hematocolpos), but it is not acquired after an abortion. * **Bicornuate Uterus:** This is a congenital Mullerian duct anomaly where the uterus is heart-shaped with two horns. While it can lead to recurrent pregnancy loss or malpresentation, it does not cause secondary amenorrhea or adhesions. **High-Yield Clinical Pearls for NEET-PG:** * **Gold Standard Investigation:** Hysteroscopy is the gold standard for both diagnosis and treatment (adhesiolysis) of Asherman’s Syndrome. * **HSG Finding:** Classically shows "filling defects" within the uterine cavity. * **Treatment:** Hysteroscopic adhesiolysis followed by the placement of an IUCD or Foley catheter and high-dose estrogen therapy to promote endometrial regrowth. * **Amniotic Band Syndrome** is a different entity; do not confuse it with intrauterine synechiae.

Q: Which of the following statements regarding spasmodic dysmenorrhea is false?

Pain persists for 2-3 days. ### Explanation **Spasmodic (Primary) Dysmenorrhea** is characterized by painful uterine contractions caused by the release of **Prostaglandin F2α (PGF2α)** from the secretory endometrium. #### Why Option C is False (The Correct Answer) In spasmodic dysmenorrhea, the pain typically begins a few hours before or exactly at the onset of menstruation. Crucially, the pain is **short-lived**, usually lasting only **12 to 24 hours**. It rarely persists beyond the first 48 hours. If pain persists for 2–3 days or longer, clinicians should suspect **Congestive (Secondary) Dysmenorrhea**, often associated with conditions like endometriosis or PID. #### Analysis of Other Options * **A. Often cured by delivery:** This is **true**. Vaginal delivery causes stretching of the adrenergic nerves in the isthmus and cervix (Frankenhauser’s plexus) and widens the cervical canal, which significantly reduces or eliminates primary dysmenorrhea. * **B. Pain appears on the first day:** This is **true**. The pain is spasmodic/colicky in nature and coincides with the peak of prostaglandin release and the heaviest menstrual flow on day one. * **D. Rare above the age of 35:** This is **true**. Primary dysmenorrhea typically begins shortly after menarche (once ovulatory cycles are established) and tends to improve with increasing age and parity. #### High-Yield Clinical Pearls for NEET-PG * **Mechanism:** High levels of PGF2α → Uterine hypercontractility → Ischemia → Pain. * **Prerequisite:** It occurs only in **ovulatory cycles** (Progesterone is required for PGF2α production). * **First-line Treatment:** NSAIDs (Mefenamic acid), which act as prostaglandin synthetase inhibitors. * **Drug of Choice for Contraception Seekers:** Combined Oral Contraceptive Pills (OCPs), which induce anovulation.

Question 1

Withdrawal bleeding with progesterone is seen in an otherwise amenorrheic woman due to which of the following?

Accepted Answer

Anovulation

Answer

Hypogonadotropic hypogonadism

Answer

Ovarian failure

Answer

Tuberculous endometritis

Question 2

A 48-year-old woman, P2L2, with menorrhagia, diagnosed with adenomyosis, is not responding to medical management with NSAIDs and hormonal therapy. What is the next step in management?

Accepted Answer

Hysteroscopy biopsy

Answer

Mirena (LNG IUD) insertion

Answer

GnRH analogues

Answer

Hysterectomy

Question 3

Which of the following IUDs is used for patients with menorrhagia?

Accepted Answer

Progestase (Levonorgestrel)

Answer

CuT 250

Answer

Multiload

Answer

Nova T

Question 4

A 34-year-old woman presents with abnormal uterine bleeding. Which of the following is the LEAST likely cause of abnormal bleeding in this age group?

Accepted Answer

Endometrial atrophy

Answer

Adenomyosis

Answer

Fibroids

Answer

Polyps

Question 5

In a patient with secondary amenorrhea who does not experience withdrawal bleeding after estrogen and progesterone administration, the underlying issue is most likely at which level?

Accepted Answer

Endometrium

Answer

Pituitary

Answer

Hypothalamus

Answer

Ovary

Question 6

What is the preferred method of contraception for managing menorrhagia?

Accepted Answer

Levonorgestrel-releasing IUD (LNG IUD)

Answer

Modified IUD

Answer

Cu-T

Answer

Condom

Question 7

Massive painless vaginal bleeding after a 6-8 week period of amenorrhea, in a premenopausal woman, is suggestive of?

Accepted Answer

Metropathia haemorrhagica

Answer

Irregular ripening

Answer

Irregular shedding (Halban Disease)

Answer

Endometrial carcinoma

Question 8

Which of the following is NOT a feature of Metropathia haemorrhagica?

Accepted Answer

Occurs in younger women

Answer

Uterus is bulky

Answer

Menorrhagia

Answer

Endometrial hyperplasia

Question 9

Secondary amenorrhea after abortion due to intrauterine adhesions is seen in:

Accepted Answer

Asherman's syndrome

Answer

Uterine inertia

Answer

Imperforate hymen

Answer

Bicornuate uterus

Question 10

Which of the following statements regarding spasmodic dysmenorrhea is false?

Accepted Answer

Pain persists for 2-3 days

Answer

Often cured by delivery of a child

Answer

Pain usually appears on the first day of menstruation

Answer

Rare above the age of 35 years

Menstrual Disorders — MCQs

Menstrual Disorders — MCQs

On this page

Practice by Chapter

Want unlimited practice?